Clinical trials: Pulmonary Function Assessment
- Condition Pulmonary Function Assessment
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Pulmonary Disease, Chronic Obstructive
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, 3-way crossover study to evaluate the lung function response to UMEC 62.5 mcg, VI 25 mcg, and UMEC/VI 62.525 mcg, administered once-daily via a novel dry powder inhaler (NDPI) over…
- Trial name
- NCT02014480
- Testing
- Umeclidinium 62.5 mcg, Vilanterol 25 mcg, Umeclidinium/Vilanterol 62.5/25 mcg
- Where
- 21 sites in Slovakia, Ukraine
- Volunteers
- 207 people
- Sponsor
- GlaxoSmithKline
COPD
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003 and…
- Trial name
- NCT02347085
- Testing
- GFF MDI (PT003)
- Volunteers
- 43 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, double-dummy, parallel group study. The purpose of this study is to compare the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) and fluticasone propionate/salmeterol (FSC)…
- Trial name
- NCT01817764
- Testing
- Umeclidinium/vilanterol, Fluticasone propionate/salmeterol
- Where
- 59 sites in United States, Argentina and 5 more
- Volunteers
- 707 people
- Sponsor
- GlaxoSmithKline
COPD
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo
Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003…
- Trial name
- NCT02347072
- Testing
- GFF MDI (PT003), Spiriva® Respimat® (Tiotropium Bromide)
- Volunteers
- 80 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a…
- Trial name
- NCT01627327
- Testing
- fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
- Where
- 54 sites in United States, Canada and 4 more
- Volunteers
- 623 people
- Sponsor
- GlaxoSmithKline
Lung Transplantation
Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients
This trial evaluated the efficacy of an everolimus-based quadruple low immunosuppressive regimen versus a standard immunosuppressive regimen concerning kidney function in lung transplant recipients.
- Trial name
- 4EVERLUNG (NCT01404325)
- Testing
- standard therapy, Everolimus
- Where
- 9 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
NVA237 BID Versus Placebo Twelve-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01715298
- Testing
- NVA237
- Where
- 59 sites in United States
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Umeclidinium/vilanterol (UMEC/VI) is a combination product under development that is used for the treatment of airflow obstruction in patients with COPD.
- Trial name
- NCT01879410
- Testing
- UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
- Where
- 72 sites in United States, Chile and 5 more
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
The purpose of this study is to evaluate the efficacy and safety of VX-661 in combination with ivacaftor (IVA, VX-770) and IVA monotherapy in participants with Cystic Fibrosis (CF) who are heterozygous for F508del-CFTR allele and…
- Trial name
- NCT02392234
- Testing
- VX-661/Ivacaftor, Ivacaftor
- Where
- 93 sites in United States, Australia and 9 more
- Volunteers
- 248 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Disease, Chronic Obstructive
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg…
- Trial name
- NCT02184611
- Testing
- Umeclidinium bromide
- Where
- 26 sites in China, South Korea
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323634
- Testing
- Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
- Where
- 50 sites in United States, Czechia and 4 more
- Volunteers
- 519 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)
Real-world data on the effects of a fixed-dose combination Long-acting beta agonists + long-acting antimuscarinic agent (LABA+LAMA) therapy with tiotropium and olodaterol administered in a single device, in COPD patients who need…
- Trial name
- NCT02719639
- Where
- 9 sites in Austria, Czechia and 7 more
- Volunteers
- 7,443 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy
The decrease in physical activity due to increasing dyspnoea that over time leads to a steadily worsening condition and increasing restriction of physical functioning is a key problem for COPD patients and affects even the early…
- Trial name
- NCT02173769
- Testing
- Spiriva® Respimat®, Striverdi® Respimat®
- Where
- 701 sites in Germany
- Volunteers
- 1,845 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
- Trial name
- NCT00645788
- Testing
- Ciprofloxacin (Cipro Inhale, BAYQ3939)
- Where
- 86 sites in United States, Australia and 7 more
- Volunteers
- 288 people
- Sponsor
- Bayer
Hepatic Impairment
Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted…
- Trial name
- NCT05005312
- Testing
- PF-07321332, Ritonavir
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
The purpose of this study was to assess global ventilated lung volume in moderate to severe COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.
- Trial name
- NCT02634983
- Testing
- QVA149
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of MEDI3506 in adult participants…
- Trial name
- FRONTIER-3 (NCT04570657)
- Testing
- MEDI3506
- Where
- 65 sites in United States, Argentina and 5 more
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, COPD
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT02449018
- Testing
- QBW251
- Where
- 16 sites in United States, Poland
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus maximum…
- Trial name
- ZENITH (NCT04896008)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Disease, Chronic Obstructive
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients…
- Trial name
- NCT00144339
- Testing
- tiotropium
- Where
- 490 sites in United States, Argentina and 35 more
- Volunteers
- 5,993 people
- Sponsor
- Boehringer Ingelheim